inp105
Acute Agitation
Impel PharmaceuticalsPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Acute Agitation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olanzapine Qilu Pharmaceutical Co., Ltd. | Phase 3 | BB |
Haloperidol Qilu Pharmaceutical Co., Ltd. | Phase 3 | B |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →